Abstract
A surrogate endpoint for overall survival (OS) could inform risk-based treatment decisions and provide early signals of efficacy to accelerate drug development for non-small cell lung cancer (NSCLC). We evaluated the utility of longitudinal circulating tumor (ct)DNA testing to predict OS and progression-free survival (PFS) in IMpower150, a phase III randomized controlled study of first-line (1L) chemotherapy plus atezolizumab and/or bevacizumab in patients with metastatic non-squamous NSCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
